ArticleESC heart failure2025
GEO combined with quantitative protein trait loci identify causative proteins in hypertrophic cardiomyopathy.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GEO combined with quantitative protein trait loci identify causative proteins in hypertrophic cardiomyopathy.ESC heart failure · 2025Article
- Integrating bioinformatics and molecular experiments to reveal the critical role of the cellular energy metabolism-related marker PLA2G1B in COPD epithelial cells.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHypertrophic cardiomyopathy (HCM) is a rare genetic heart disease characterized by a limited patient population and scarce research and treatment resources. This study aimed to identify HCM-associated proteins by integrating cardiac tissue data from the Gene Expression Omnibus (GEO) database with the latest protein quantitative trait locus (pQTL) dataset. METHODS AND
resultsWe analysed data from the GEO database. The GSE36961 dataset included 106 HCM samples and 39 healthy controls. The GSE180313 dataset included 13 HCM samples and 7 healthy controls. pQTL data were obtained from the plasma of 54 000 UK Biobank participants, covering 1463 proteins. HCM genome-wide association study (GWAS) data were sourced from the FinnGen study, which included 1125 HCM cases and 411 056 controls. We analysed the GEO dataset of cardiac tissue from HCM patients to identify differentially expressed genes (DEGs). These DEGs were compared with pQTL data to identify protein phenotypes suitable for Mendelian randomization (MR) analysis. A two-sample MR analysis was performed to assess the causal association between these protein phenotypes and HCM. The robustness of the study results was further assessed through sensitivity analysis of heterogeneity and horizontal pleiotropy tests. Two proteins were identified as causally associated with HCM risk: carbonic anhydrase 3 (CA3) [inverse variance weighted (IVW): odds ratio (OR) = 1.292, 95% confidence interval (CI) = 1.021-1.636, P = 0.033] and serpin family E member 1 (SERPINE1) [IVW: OR = 1.313, 95% CI = 1.063-1.621, P = 0.011]. Both proteins were associated with increased HCM risk, with no significant heterogeneity (P > 0.05) or evidence of horizontal pleiotropy (P > 0.05).
conclusionsCA3 and SERPINE1 proteins may exert causal effects on HCM and may serve as characteristic markers and therapeutic targets for this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.